This study is for young patients with a type of cancer called neuroblastoma or ganglioneuroblastoma. The cancer is considered high-risk, meaning it's more serious. Doctors are testing new treatments to see if they work better than the usual ones. One treatment being tested is iobenguane I-131, which is a radioactive medicine that targets only cancer cells. Another treatment is lorlatinib, a drug that stops cancer cells from growing. The study wants to find out if adding these treatments helps patients live longer without the cancer coming back.

• The study involves different treatment plans, and patients will be assigned to one based on their needs.
• Participants will have regular medical check-ups, including scans and blood tests, for up to 60 months.
• There are potential risks and side effects, such as toxicities associated with new treatments.

It is important for families to discuss with doctors about the potential benefits and risks before participating in the study. The study is open to patients between 1 and 30 years old, who meet specific health conditions. Pregnant or breastfeeding patients cannot participate.